​

Funding Round

Series B - Obsidian Therapeutics

Series B - Obsidian Therapeutics

Investment Firm

Overview

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.

Announced Date

Sep 09, 2021

Funding Type

Series B

Highlights

N/A

Location

N/A

Social

N/A

Investor Lead

The Column Group

The Column Group

The Column Group is a early_stage_venture and late_stage_venture and post_ipo and private_equity and seed firm.

Participant Investors

10

Investor Name
Participant InvestorTCG Crossover
Participant InvestorPivotal bioVenture Partners
Participant InvestorBristol-Myers Squibb
Participant InvestorThe Column Group
Participant InvestorAtlas Venture

Round Details and Background

Obsidian Therapeutics raised $115000000 on 2021-09-09 in Series B

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Dec 06, 2017
Series A - Obsidian Therapeutics
9-49.5M
Sep 09, 2021
Series B - Obsidian Therapeutics
14-115.0M
Apr 03, 2024
Series C - Obsidian Therapeutics
17-160.5M

Recent Activity

There is no recent news or activity for this profile.